Axa raised its position in Halyard Health Inc (NYSE:HYH) by 33.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 190,400 shares of the medical instruments supplier’s stock after purchasing an additional 47,600 shares during the quarter. Axa’s holdings in Halyard Health were worth $8,793,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of HYH. Jarislowsky Fraser Ltd bought a new position in shares of Halyard Health during the third quarter worth about $200,000. Jane Street Group LLC bought a new position in shares of Halyard Health during the third quarter worth about $211,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Halyard Health during the second quarter worth about $217,000. Ramsey Quantitative Systems bought a new position in shares of Halyard Health during the fourth quarter worth about $266,000. Finally, Crossmark Global Holdings Inc. bought a new position in shares of Halyard Health during the third quarter worth about $280,000. Hedge funds and other institutional investors own 91.34% of the company’s stock.
A number of brokerages have recently issued reports on HYH. TheStreet upgraded Halyard Health from a “c+” rating to a “b” rating in a research report on Monday, December 4th. Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “strong-buy” rating and set a $54.00 price objective for the company in a research report on Friday, March 2nd. Finally, ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $49.33.
Halyard Health Inc (NYSE:HYH) opened at $49.20 on Tuesday. Halyard Health Inc has a 1 year low of $35.24 and a 1 year high of $50.99. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.74 and a current ratio of 2.98. The stock has a market capitalization of $2,267.65, a PE ratio of 29.46, a PEG ratio of 5.66 and a beta of 1.60.
Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.23. Halyard Health had a return on equity of 6.98% and a net margin of 5.82%. The company had revenue of $428.10 million during the quarter, compared to the consensus estimate of $413.94 million. During the same period last year, the company earned $0.50 earnings per share. The firm’s revenue was up 4.4% compared to the same quarter last year. research analysts predict that Halyard Health Inc will post 0.96 EPS for the current fiscal year.
WARNING: This piece of content was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://ledgergazette.com/2018/03/13/axa-boosts-holdings-in-halyard-health-inc-hyh.html.
Halyard Health Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Want to see what other hedge funds are holding HYH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halyard Health Inc (NYSE:HYH).
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.